Colposcopic biopsy findings in ASCUS or normal cervical cytology patients with high-risk HPV positivity

The aim of the present study was to compare colposcopic biopsy results of women in Turkey with normal cervical cytology and Atypical Squamous Cells of Undetermined Significance (ASCUS) who had human papilloma virus (HPV) genotypes 16, 18 and combined 16/18. The overarching goal was to enhance the existing body of evidence on cervical cancer screening strategies, with an ultimate aim of refining HPV testing guidelines and improving patient management. In this retrospective study, we examined the medical records of 1121 patients from a tertiary health care setting who tested positive for HPV 16, HPV 18 or both, and who exhibited ASCUS or normal Pap smear findings. A detailed review of the patients’ colposcopic biopsy outcomes was conducted, with particular attention to their HPV genotype status and the impact of smoking. The 1121 patients were classified based on HPV genotype into three groups: HPV 16 (78.5%), HPV 18 (15.8%), and co-infection with HPV 16 and 18 (5.7%). On the basis of smear characteristics, patients were categorized as normal (81.4%) and ASCUS (18.2%). Approximately 40% of patients infected with HPV 16, HPV 18 or both with no evidence of intraepithelial lesion or malignancy (NILM) or ASCUS on Pap smear had High-grade Squamous Intraepithelial Lesion cancer on biopsy. Notably, for those with normal smear results, the rate of Low-grade Squamous Intraepithelial Lesion biopsy was approximately 15% higher in the HPV 18 group than the HPV 16 group (59.6% vs. 45.8%; p = 0.023). Smoking prevalence was significantly higher in the co-infected HPV 16/18 group (p = 0.013). This study underscores the importance of vigilant HPV and cytology testing, especially for individuals with HPV 16/18, regardless of normal cytology findings.

HPV 16/18; Colposcopic biopsy; HSIL; LSIL; Cytology screening

[1] Zhang H, Tang M, Jiang Y, Cai J. Comment on: “Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis”. Archives of Gynecology and Obstetrics. 2022; 306: 1829.

[2] Kabaca C, Giray B, Guray Uzun M, Akis S, Purut YE, Keles Peker E, et al. The meaning of high-risk HPV other than type 16/18 in women with negative cytology: is it really safe to wait for 1 year? Diagnostic Cytopathology. 2021; 49: 480–486.

[3] Kahraman A, Tülek F. Analysis of the association between minor cervical cytological abnormalities and consequent pathology results according to HPV types. Southern Clinics of Istanbul Eurasia. 2021; 32: 371–375.

[4] Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American cancer society, american society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. American Journal of Clinical Pathology. 2012; 137: 516–542.

[5] Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. Journal of Clinical Microbiology. 2015; 53: 52–59.

[6] MacLaughlin KL, Jacobson RM, Radecki Breitkopf C, Wilson PM, Jacobson DJ, Fan C, et al. Trends over time in pap and pap-HPV cotesting for cervical cancer screening. Journal of Women’s Health. 2019; 28: 244–249.

[7] Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions. Journal of Lower Genital Tract Disease. 2012; 16: 205–242.

[8] Khan MJ, Werner CL, Darragh TM, Guido RS, Mathews C, Moscicki A, et al. ASCCP colposcopy standards: role of colposcopy, benefits, potential harms, and terminology for colposcopic practice. Journal of Lower Genital Tract Disease. 2017; 21: 223–229.

[9] Yalcin I, Sari ME, Sahin H, Gultekin M, Gungor T, Meydanli MM. Colposcopic biopsy findings among women with either HPV-16 only or HPV-18 only who have normal cervical cytology. International Journal of Gynecology & Obstetrics. 2018; 143: 300–305.

[10] Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk. European Journal of Cancer Prevention. 2016; 25: 232–238.

[11] Wang Z, Liu T, Wang Y, Gu Y, Wang H, Liu J, et al. Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China. Infectious Agents and Cancer. 2020; 15: 34.

[12] Takamatsu R, Nabandith V, Pholsena V, Mounthisone P, Nakasone K, Ohtake K, et al. Cervical cytology and human papillomavirus among asymptomatic healthy volunteers in Vientiane, Lao PDR. BMC Cancer. 2017; 17: 872.

[13] Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: epidemiology, risk factors and screening. Chinese Journal of Cancer Research. 2020; 32: 720–728.

[14] Wright TC, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. American Journal of Clinical Pathology. 2011; 136: 578–586.

[15] Moore KN, Cofer AM, Elliot L, Lanneau GS, Downing KA, Walker JL, et al. High prevalence of cervical intraepithelial neoplasia 2/3 among adolescents discovered with biopsy at time of incident colposcopic evaluation. Journal of Lower Genital Tract Disease. 2006; 10: 182.

[16] Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, et al. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus—based screening in Mexico. JAMA Network Open. 2019; 2: e1915781.

[17] Gallegos-Bolaños J, Rivera-Domínguez JA, Presno-Bernal JM, Cervantes-Villagrana RD. High prevalence of co-infection between human papillomavirus (HPV) 51 and 52 in Mexican population. BMC Cancer. 2017; 17: 531.

[18] Liao G, Jiang X, She B, Tang H, Wang Z, Zhou H, et al. Multi-infection patterns and co-infection preference of 27 human papillomavirus types among 137,943 gynecological out patients across China. Frontiers in Oncology. 2020; 10: 449.

[19] Tantengco OAG, Nakura Y, Yoshimura M, Nishiumi F, Llamas-Clark EF, Yanagihara I. Co-infection of human papillomavirus and other sexually transmitted bacteria in cervical cancer patients in the Philippines. Gynecologic Oncology Reports. 2022; 40: 100943.

[20] Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer—a systematic review & meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020; 247: 163–175.

[21] Aydogan Kirmizi D, Baser E, Demir Caltekin M, Onat T, Sahin S, Yalvac ES. Concordance of HPV, conventional smear, colposcopy, and conization results in cervical dysplasia. Diagnostic Cytopathology. 2021; 49: 132–139.

[22] Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. American Journal of Obstetrics and Gynecology. 2013; 208: 184.e1–184.e11.